Life (Jan 2022)

Predictive Value of Circulating Tumor Cells Detected by ISET<sup>®</sup> in Patients with Non-Metastatic Prostate Cancer Undergoing Radical Prostatectomy

  • Laura Nalleli Garrido Castillo,
  • Arnaud Mejean,
  • Philippe Vielh,
  • Julien Anract,
  • Alessandra Decina,
  • Bertrand Nalpas,
  • Naoual Benali-Furet,
  • Isabelle Desitter,
  • Patrizia Paterlini-Bréchot

DOI
https://doi.org/10.3390/life12020165
Journal volume & issue
Vol. 12, no. 2
p. 165

Abstract

Read online

There is an unmet need for reliable biomarkers to predict prostate cancer recurrence after prostatectomy in order to better guide the choice of surgical treatment. We have evaluated the predictive value of the preoperative detection of Circulating Tumor Cells (CTC) for prostate cancer recurrence after surgery. A cohort of 108 patients with non-metastatic prostate adenocarcinoma undergoing radical prostatectomy was tested for the presence of CTC before prostatectomy using ISET®. Disease recurrence was assessed by the increase in serum PSA level after prostatectomy. The following factors were assessed for statistical association with prostate cancer recurrence: the presence of CTC, serum PSA, Gleason score, and pT stage using univariate and multivariate analyses, with a mean follow-up of 34.9 months. Prostate cancer recurrence was significantly associated with the presence of at least 1 CTC at the preoperative time point (p p ® before surgery is an interesting candidate predictive marker for cancer recurrence in patients with non-metastatic PCa.

Keywords